|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:approvalYear
|
2020
|
|
gptkbp:ATCCode
|
J05AB16
|
|
gptkbp:bioavailability
|
low (oral)
|
|
gptkbp:CASNumber
|
1809249-37-3
|
|
gptkbp:color
|
white to off-white
|
|
gptkbp:contraindication
|
hypersensitivity to remdesivir
|
|
gptkbp:drugClass
|
antiviral drug
|
|
gptkbp:eliminatedIn
|
renal
|
|
gptkbp:eliminationHalfLife
|
1 hour (remdesivir), 25 hours (GS-441524)
|
|
gptkbp:form
|
solution for injection
lyophilized powder
|
|
gptkbp:hasFirstApprovalCountry
|
gptkb:United_States
|
|
gptkbp:hasFirstApprovalDate
|
2020-10-22
|
|
gptkbp:hasInChIKey
|
RWWYLEGWBNMMLJ-YSOARWBDSA-N
|
|
gptkbp:hasMetabolite
|
gptkb:GS-441524
|
|
gptkbp:hasMolecularFormula
|
C27H35N6O8P
|
|
gptkbp:hasPatentExpiry
|
2035
|
|
gptkbp:hasPatentHolder
|
gptkb:Gilead_Sciences
|
|
gptkbp:hasPharmacodynamics
|
inhibits viral replication
|
|
gptkbp:hasPharmacokinetics
|
rapidly metabolized to active nucleoside analog
|
|
gptkbp:hasResearchUse
|
investigational for other viral infections
|
|
gptkbp:hasSMILES
|
CC(C)[C@@H](NC(=O)[C@@H](N)C(C)C)P(=O)(OCC1=CN(C2=NC=NC(=C21)N)C3CC3)OCC4=CC=CC=C4
|
|
gptkbp:hasStorageCondition
|
store at 20°C to 25°C
|
|
gptkbp:hasUNII
|
53J0A3T31S
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
DB13904
|
|
gptkbp:indication
|
gptkb:COVID-19
gptkb:Ebola_virus_infection
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:manufacturer
|
gptkb:Gilead_Sciences
|
|
gptkbp:mechanismOfAction
|
RNA polymerase inhibitor
|
|
gptkbp:molecularWeight
|
602.6 g/mol
|
|
gptkbp:name
|
gptkb:Remdesivir
|
|
gptkbp:pregnancyCategory
|
Not assigned
|
|
gptkbp:PubChem_CID
|
gptkb:DB13904
121304016
CHEMBL2016761
D11472
58191791
|
|
gptkbp:routeOfAdministration
|
intravenous
|
|
gptkbp:sideEffect
|
nausea
elevated liver enzymes
hypersensitivity
|
|
gptkbp:status
|
FDA approved
|
|
gptkbp:synonym
|
gptkb:GS-5734
|
|
gptkbp:target
|
RNA-dependent RNA polymerase
|
|
gptkbp:therapeuticArea
|
gptkb:disease
|
|
gptkbp:bfsParent
|
gptkb:emicizumab
|
|
gptkbp:bfsLayer
|
8
|